The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal
Pharmacology Biochemistry and Behavior · 2023
DOI: 10.1016/j.pbb.2023.173525 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2023. Verfasst von Alok De und 1 weiteren Autor:innen. Beteiligte Einrichtung: Substance Use Research Laboratory, Kansas City Veterans Affairs Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, United States of Ameri…. Hauptthemen laut MEDLINE: Melatonin, Substance Withdrawal Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIDA NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Exogenous melatonin appears to have anti-addictive properties and was recently shown to improve mental health and metabolic measures in patients receiving chronic opioid maintenance therapy. Agomelatine is a marketed antidepressant which acts as a melatonin agonist. We evaluated its effects using a rat model of morphine-reinforced behavior. METHODS: After pretreatment with noncontingent morphine, male Wistar rats were trained to self-administer intravenous morphine (1.0 mg/kg-injection) under a progressive-ratio schedule. Rats were pretreated with vehicle or agomelatine during extinction, reinstatement, and reacquisition of morphine-reinforced behavior. RESULTS: Daily treatment with 10 mg/kg-day of agomelatine decreased the number of ratios completed and prolonged latency during morphine-induced reinstatement. There were no significant effects on cue-induced reinstatement, morphine self-administration, or naloxone-precipitated withdrawal. Treatment with 32 mg/kg-day of agomelatine caused postural changes. That dose prolonged withdrawal-induced loss of body weight and caused delayed reductions in food reinforcement. SUMMARY: In addition to postural effects, high-dose agomelatine worsened the course of spontaneous withdrawal and produced nonspecific effects on food-reinforced behavior. When administered at a selective dose, agomelatine did not modify morphine self-administration or precipitated withdrawal, but decreased morphine-induced reinstatement. Our findings show potential detrimental effects of high-dose agomelatine, with reductions in opioid-seeking behavior after a lower, more selective dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Substance Use Research Laboratory, Kansas City Veterans Affairs Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, United States of America.
- Substance Use Research Laboratory, Kansas City Veterans Affairs Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, United States of America; Division of Clinical Pharmacology, Department of Medicine, Univers…
Förderung
- BLRD VA
- NIDA NIH HHS
Zitieren
APA
De, A., & Grasing, K. W. (2023). The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2023.173525
Vancouver
De A, Grasing KW. The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal. Pharmacology Biochemistry and Behavior. 2023. doi:10.1016/j.pbb.2023.173525
BibTeX
@article{De2023,
author = {De, Alok and Grasing, Ken W},
title = {The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal},
journal = {Pharmacology Biochemistry and Behavior},
year = {2023},
doi = {10.1016/j.pbb.2023.173525}
}
EUVIMED